Appointments: Changes At Hikma, Bluebird Bio, Celgene, Alkermes, Cell Medica, Editas Medicine, Futura Medical, Corline Biomedical And Horizon Discovery
Pharma and biotech appointments this week include a new CEO at Hikma and an interim-CEO at Horizon Discovery, a Chief Commercial Officer for bluebird bio, and new board directors at Celgene, Alkermes, Editas Medicine, and Futura Medical.
You may also be interested in...
The market slump at the beginning of February affected virtually all of the stocks of the top 50 pharmaceutical companies. But unpredicted clinical successes or surprisingly good financials still kept a few companies above water.
Pipeline Watch is a weekly snapshot of selected late-stage clinical trial events and approvals announced by pharmaceutical and biotech companies at medical and industry conferences, in financial and company presentations, and in company releases and statements.
The foundation is donating to help supply Merck/Ridgeback’s antiviral to low-income nations; also Pfizer got one step closer to full approval for booster shots of Comirnaty, while the FDA authorized Moderna and J&J boosters, and Daiichi Sankyo made progress on its own mRNA vaccine candidate. Shionogi's once-daily oral antiviral is also moving forward.